683 related articles for article (PubMed ID: 12438234)
41. Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases.
Yantiss RK; Oh KY; Chen YT; Redston M; Odze RD
Am J Surg Pathol; 2007 Aug; 31(8):1238-45. PubMed ID: 17667549
[TBL] [Abstract][Full Text] [Related]
42. Tracing origin of serrated adenomas with BRAF and KRAS mutations.
Lee EJ; Choi C; Park CK; Maeng L; Lee J; Lee A; Kim KM
Virchows Arch; 2005 Sep; 447(3):597-602. PubMed ID: 15991007
[TBL] [Abstract][Full Text] [Related]
43. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
[TBL] [Abstract][Full Text] [Related]
45. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Lee JW; Soung YH; Seo SH; Kim SY; Park CH; Wang YP; Park K; Nam SW; Park WS; Kim SH; Lee JY; Yoo NJ; Lee SH
Clin Cancer Res; 2006 Jan; 12(1):57-61. PubMed ID: 16397024
[TBL] [Abstract][Full Text] [Related]
46. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.
Matos P; Oliveira C; Velho S; Gonçalves V; da Costa LT; Moyer MP; Seruca R; Jordan P
Gastroenterology; 2008 Sep; 135(3):899-906. PubMed ID: 18602919
[TBL] [Abstract][Full Text] [Related]
47. Frequent activating GNAS mutations in villous adenoma of the colorectum.
Yamada M; Sekine S; Ogawa R; Taniguchi H; Kushima R; Tsuda H; Kanai Y
J Pathol; 2012 Sep; 228(1):113-8. PubMed ID: 22374786
[TBL] [Abstract][Full Text] [Related]
48. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency.
Oliveira C; Pinto M; Duval A; Brennetot C; Domingo E; Espín E; Armengol M; Yamamoto H; Hamelin R; Seruca R; Schwartz S
Oncogene; 2003 Dec; 22(57):9192-6. PubMed ID: 14668801
[TBL] [Abstract][Full Text] [Related]
49. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
50. Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis.
Takane K; Matsusaka K; Ota S; Fukuyo M; Yue Y; Nishimura M; Sakai E; Matsushita K; Miyauchi H; Aburatani H; Nakatani Y; Takayama T; Matsubara H; Akagi K; Kaneda A
Oncotarget; 2016 Dec; 7(51):84003-84016. PubMed ID: 27563825
[TBL] [Abstract][Full Text] [Related]
51. BRAF and KRAS mutations in prostatic adenocarcinoma.
Cho NY; Choi M; Kim BH; Cho YM; Moon KC; Kang GH
Int J Cancer; 2006 Oct; 119(8):1858-62. PubMed ID: 16721785
[TBL] [Abstract][Full Text] [Related]
52. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
[TBL] [Abstract][Full Text] [Related]
53. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
54. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
[TBL] [Abstract][Full Text] [Related]
55. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma.
Yagi K; Takahashi H; Akagi K; Matsusaka K; Seto Y; Aburatani H; Nakajima A; Kaneda A
Am J Pathol; 2012 Feb; 180(2):616-25. PubMed ID: 22115708
[TBL] [Abstract][Full Text] [Related]
56. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
57. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
[TBL] [Abstract][Full Text] [Related]
58. BRAF inhibitor treatment of melanoma causing colonic polyps: An alternative hypothesis.
Kelleher FC; Callaghan G; Gallagher C; O'Sullivan H
World J Gastroenterol; 2017 May; 23(17):3022-3029. PubMed ID: 28533659
[TBL] [Abstract][Full Text] [Related]
59. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
[TBL] [Abstract][Full Text] [Related]
60. B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Jaworski M; Buchmann A; Bauer P; Riess O; Schwarz M
Oncogene; 2005 Feb; 24(7):1290-5. PubMed ID: 15592514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
